Clinical trials: Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Condition Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Funder type Industry (pharma, biotech, devices)
Non-squamous Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally…
- Trial name
- NCT06627647
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 301 sites in United States, Argentina and 23 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants…
- Trial name
- DESTINY-Lung06 (NCT06899126)
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed
- Where
- 246 sites in United States, Argentina and 22 more
- Volunteers
- 686 people
- Sponsor
- Daiichi Sankyo
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver.
- Trial name
- NCT03468426
- Testing
- BI 836880, Ezabenlimab
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 252 people
- Sponsor
- Boehringer Ingelheim
NSCLC, Non-small Cell Lung Cancer
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with…
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- RASolve 308 (NCT07777822)
- Testing
- zoldonrasib, pembrolizumab, pemetrexed + cisplatin /carboplatin
- Where
- 4 sites in United States
- Volunteers
- 430 people
- Sponsor
- Revolution Medicines, Inc.
Non-Small Cell Lung Cancer, Colorectal Cancer
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT07216105
- Testing
- FT836, Cetuximab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- Fate Therapeutics
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of…
- Conditions
- Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00596830
- Testing
- CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
- Where
- 280 sites in United States, Australia and 24 more
- Volunteers
- 681 people
- Sponsor
- Pfizer
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without…
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
- Trial name
- NCT06427941
- Testing
- BGB-B2033, Tislelizumab, Bevacizumab
- Where
- 51 sites in United States, Brazil and 7 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin…
- Trial name
- NCT00974584
- Testing
- GDC-0941, bevacizumab, carboplatin
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Solid Tumors, Colorectal Cancer
First in Human Study of QLS5316 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and…
- Conditions
- Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT07358884
- Testing
- QLS5316
- Volunteers
- 300 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055887
- Testing
- carboplatin, cisplatin, efaproxiral
- Where
- 22 sites in United States, Belgium and 2 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs.
- Trial name
- NCT07459751
- Testing
- HLX43, HLX43+HLX07, Docetaxel
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Non-Small Cell Lung Cancer
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT06933329
- Testing
- Zelenectide pevedotin
- Where
- 3 sites in France, Spain
- Volunteers
- 73 people
- Sponsor
- BicycleTx Limited
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage…
- Trial name
- NCT03663205
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- 47 sites in China
- Volunteers
- 334 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced…
- Trial name
- NCT07464327
- Testing
- HS-20093, Docetaxel
- Volunteers
- 450 people
- Sponsor
- Hansoh BioMedical R&D Company
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Carcinoma, Non-Small-Cell Lung
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care…
- Trial name
- MISSION (NCT00863746)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 182 sites in United States, Argentina and 32 more
- Volunteers
- 703 people
- Sponsor
- Bayer
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT05565417
- Testing
- IMT-009, Fruquintinib
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Immunitas Therapeutics